Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy

Fig. 1

Effects of anagliptin and sitagliptin on FABP4 level. a Concentrations of FABP4 at baseline and 52 weeks in patients treated with anagliptin (n = 148, male/female: 89/59) and sitagliptin (n = 159, male/female: 93/66). b Comparison of change in FABP4 level between the anagliptin and sitagliptin treatment groups. Values are shown as mean ± SE. *P < 0.05

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840